Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant strides in recent years, positioning itself as a frontrunner in the industry.

Securities adjusted its outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $130 from $110 while ...

Sarasota Memorial Hospital has earned the #1 spot among the world's WATCHMAN providers protecting people with atrial ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

The company states: “Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN FLX Left Atrial Appendage Closure Device ...

System* and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device, respectively, during a late-breaking science session at AF Symposium 2025. Boston Scientific Corporation (NYSE ...

Boston Scientific projected full-year revenue growth between 12.5% and 14.5%, compared with the prior year. The company's key growth drivers include its stroke prevention device, Watchman ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...